Navigation Links
Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
Date:4/15/2008

outcomes.

Numerous scientific and medical articles have described the usefulness of temperature modulation, such as induced hypothermia (cooling), which is designed to protect endangered cells, prevent tissue death and preserve organ function following acute events associated with severe oxygen deprivation such as cardiac arrest or stroke. Therapeutic hypothermia is believed to work by protecting critical tissues and organs (such as the heart, brain, and kidneys) following ischemic or inflammatory events, by lowering metabolism and preserving cellular energy stores, thereby potentially stabilizing cellular structure and preventing or reducing injuries at the cellular, tissue and organ level. Two international clinical trials on hypothermia after cardiac arrest published in The New England Journal of Medicine demonstrated that induced hypothermia reduced mortality and improved long-term neurological function. Based on these and other results, the American Heart Association (AHA) and the International Liaison Committee on Resuscitation (ILCOR) have issued guidelines recommending that cardiac arrest victims be treated with induced hypothermia.

Ischemic diseases constitute the largest segment of the medical market in the United States and in almost all developed countries worldwide. For example, in the U.S. and other developed countries, an estimated 1.4 million people experience cardiac arrest each year, of which an increasing number (currently about 350,000) survive to receive advanced care. The AHA guidelines now recommend the use of therapeutic cooling as part of the critical care procedures for patients with an out-of-hospital cardiac arrest following ventricular fibrillation. With respect to heart attacks, an estimated 325,000 people in the U.S., and approximately 375,000 people outside the U.S., receive emergency angioplasty or anti-clotting treatment as first-line care.

In the area of stroke, approximately 700,000 Americans experience a stro
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
2. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
5. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
6. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
7. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
8. Vital Therapies Announces Presentation of ELAD(R) Artificial Liver Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
9. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
10. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
11. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)...RNewswire-FirstCall/ -- CEL-SCI Corporation,(NYSE:... Material Transfer,Agreement (MTA) with the Nation...d the laboratory of Dr. Francesco M. Marincola, M....to the tumor microenvironment,caused by CEL-SCI,s ...of,the Infectious Disease and Immunogentics Sectio...
(Date:10/7/2008)...Today at ACG Annual Scientific Meeting -, ORLANDO...Pharmaceuticals, Inc. (formerly Microbia, Inc.) an...nounced the presentation of results from a Phase,2...y in 420 patients with,irritable bowel syndrome wi...cates that once- daily oral dosing of linaclotide,...
(Date:10/7/2008)...lighting CIMZIA,s long-term benefits and value in,...ted at American College,of Gastroenterology (ACG),...ata from two studies,presented this week by UCB at...nual Meeting demonstrate that CIMZIA(R) (certolizu...mor Necrosis Factor alpha) - provides,sustained im...
(Date:10/7/2008)...rt Enrolled in Stage A of Trial Assessing Regimen ...and Paclitaxel -, TUSTIN, Calif., Oct. 7 /PRNewsw...(Nasdaq: PPHM ), a clinical stage biopharmaceutic...e treatment of cancer and,hepatitis C virus (HCV) ...nrollment in the first stage of a Phase II trial o...
Breaking Medicine Technology:CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4deCODE Files IND for DG071 a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders 3205 1deCODE Files IND for DG071 a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders 3205 2deCODE Files IND for DG071 a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders 3205 3deCODE Files IND for DG071 a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders 3205 4deCODE Files IND for DG071 a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders 3205 5So called sandfish could help materials handling and process technology specialists 5204 1So called sandfish could help materials handling and process technology specialists 5204 2So called sandfish could help materials handling and process technology specialists 5204 3Brown University and Women 26amp 3B Infants Hospital expand national childrens study to Bristol County 5202 1Brown University and Women 26amp 3B Infants Hospital expand national childrens study to Bristol County 5202 2Brown University and Women 26amp 3B Infants Hospital expand national childrens study to Bristol County 5202 3Brown University and Women 26amp 3B Infants Hospital expand national childrens study to Bristol County 5202 4Isolagen to Present at the JMP Securities Healthcare Focus Conference 8074 1Isolagen to Present at the JMP Securities Healthcare Focus Conference 8074 2
...0, 2007 - Australian,biotechnology company Avexa (... from its Phase IIb trial for apricitabine (ATC).,...ase inhibitor,(NRTI) being developed for the treat...ant HIV., The Phase IIb trial compared the effecti...ts with drug-resistant HIV with,the effectiveness ...
.../ -- Treatment of,coronary artery disease (CAD) ap...ng, according to a study published today in The,Am...on rates for heart attacks (acute myocardial,infar...ossibly due,to broader use of preventive treatment...lines in risk factors like smoking. , The study is...
Other Medicine Technology:Avexa Reports Positive Phase IIb Result 2Avexa Reports Positive Phase IIb Result 3Avexa Reports Positive Phase IIb Result 4Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 2Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 3
(Date:10/7/2008)...RNewswire-FirstCall/ -- Stallergenes S.A.,today an...greement with,Catalent for the promotion and distr...FLEX(R), co-developed and co-manufactured by Catal...sts of a syringe pre-filled with adrenaline, which....3 and 0.15 mg), in an,autoinjector device. The Me...
(Date:10/7/2008)...of asthma in a young child may well be more challe..., according to a review of research and clinical e... Indiana University School of Medicine and Riley H... issue of Clinical Pediatrics . , "Wheezing ca... Professor of Pediatrics at the IU School of Medic...
(Date:10/7/2008)...rial Specialties, Mfg. is pleased to announce the ...hese filters are exclusively available from Indust... push-to-connect style fittings integrated into th...ne filter offers versatility and customization for... (PRWEB) October 7, 2008 -- Exclusively availa...
(Date:10/6/2008)...fight against childhood obesity, researcher notes ... Three-quarters of middle schools have vending mac...new study finds. , The research demonstrates th...ls, and "that those vending machines don,t always ...y Virus, a registered dietitian with the Center fo...
Breaking Medicine News(10 mins):Health News:Stallergenes Partners With Catalent and the Medical House for Commercialization of Adrenaline Autoinjector in Europe 2Health News:Wheezing and asthma in young children 2Health News:Vending Machines Found in Most Middle Schools 2
...ing to recent update, people with type 2 diabetes ...emia) may be able to safely reduce their risk for ...ase niacin.// The finding runs counter to previous... blood sugar levels in diabetics. Certain studies,...
...ing to researchers, low body temperature, low insu...be linked to a slowdown of the aging process. It i...ses the lifespan of animals. Now researchers at th... about slowing down the aging process. They compar...
...ing to a new study, hospitals staffed with more re...- save more lives from deadly complications, and r...ify worries about the nation's growing nursing sho...s because we don't have the knowledge of the regis...
...study contributes to the findings of liver cancer....of Medicine report findings on a potential new tre...archers injected a compound called 3-bromopyruvate...cerous tumor. They say it did not adversely affect...
Other Medicine News:Health News:Nurses save more lives 2
The IDENTI-PRINT II ID system functions as a complete, hospital wide patient identification system. It integrates the benefits of bedside labeling into a multipurpose ID band that consolidates admitt
Volks drive to provide the best optics enables us to bring you a lens with the highest resolution available in a non-contact slit lamp lens. The astonishing detail allows true 3D viewing of the retin
...nting solution that can encode smart labels at the...of the most versatile in the industry! Designed fo...ands and smart labels, the R2844-Z meets the needs...d and more connectivity choices-such as standard s...
The Health Trax System includes real time location services (RTLS), long range active RFID, telemetery and choke-point visibility all in a single intergrated infrastructure. Health Trax Standards-bas
Medicine Products: